Brought to you by 
Pfizer and GlaxoSmithKline set up HIV joint venture
11 Jun 2014
Executive Summary
In a move that gives them 19% of the global HIV market, GlaxoSmithKline and Pfizer have set up a joint venture to focus on 17 of their marketed drugs and pipeline compounds for this infectious disease. Together the assets have an estimated book value of £250mm ($373mm). Some analysts say the yet-unnamed new entity may likely be spun off or sold in the future.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer and GlaxoSmithKline set up HIV joint venture
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice